Phoebe Chubb explores how digitalisation is shaking up the world of drug discovery and development by increasing productivity and reducing human error.
List view / Grid view
Filter the results
Scientists have developed a novel chimeric antigen receptor (CAR) T-cell therapy to target a variety of human and murine solid-tumour cancer cells.
The novel formulation hit peak activity at nine minutes, less than half the time taken for a commercially available formulation.
Researchers have hypothesised that treatments targeting the downregulation of AhRs and IDO1 genes could reduce severity of COVID-19 infection.
A group of researchers has used locked nucleic acid gapmer antisense oligonucleotides to treat facioscapulohumeral muscular dystrophy in cells and mice.
New research has found that of the 718 pipeline drugs associated with COVID-19, 70 percent are currently in the discovery or pre-clinical stages.
Biologics represent a growing class of drugs with indications in oncology, chronic inflammation, and autoimmune diseases.
Researchers who reported that delivering the human ACE2 protein into mouse airway cells creates COVID-19 models have released their findings to allow other scientists to make their own models.
A vaccine adjuvant named 3M-052 was able to provide rhesus monkeys with protection against HIV for over a year, a new study reports.
Keith Murphy, CEO of Viscient Biosciences, discusses the process of developing a 3D bioprinted tissue model and their potential in developing therapeutics for COVID-19 and other diseases.
Japanese researchers have shown that a silicon-based antioxidant agent can suppress the development of kidney failure and Parkinson's disease in rodent models.
A new study has shown that effective and safe M. pneumoniae vaccine could be possible by removing certain lipoproteins from the bacteria.
An analysis of papers relating to COVID-19 has found that female researchers make up a third of authors. Here, the potential reasons behind this figure are explored and a possible solution to encourage equality.
Researchers have proposed a cocktail of two antibodies which they say could provide an effective therapy for COVID-19 patients.
Small molecules named CS1 (bisantrene) and CS2 (brequinar) have been developed by researchers to suppress the growth of tumours and have shown promise in mouse models.